Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;1998(2):CD000955.
doi: 10.1002/14651858.CD000955.

Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis

J Pope  1 , D Fenlon, A Thompson, B Shea, D Furst, G Wells, A Silman
Affiliations

Cyclofenil for Raynaud's phenomenon in progressive systemic sclerosis

J Pope et al. Cochrane Database Syst Rev. 2000.

Abstract

Objectives: To assess the effects and toxicity of Cyclofenil versus placebo for the treatment of Raynaud's phenomenon (RP) in scleroderma.

Search strategy: We searched the Cochrane Controlled Trials Register, and Medline up to 1996 using the Cochrane Collaboration search strategy developed by Dickersin et al.(1994). Key words included: Raynaud's or Vasospasm, Scleroderma or Progressive Systematic Sclerosis or Connective Tissue Disease or Autoimmune Disease. Current Contents were searched up to and including April 7, 1997. All bibliographies of articles retrieved were searched and key experts in the area were contacted for additional and unpublished data. The initial search strategy included all languages.

Selection criteria: All randomized trials comparing cyclofenil versus placebo were eligible if they reported any clinical outcomes within the trial.

Data collection and analysis: Data were abstracted independently by two reviewers (DF, AT). Peto's odds ratio (OR) was calculated for all dichotomous outcomes, and a weighted mean difference was calculated for all continuous outcomes. A fixed effects or random effects model was used if the data were homogeneous or heterogeneous respectively.

Main results: One trial with 38 patients was included. There was a trend for Cyclofenil to demonstrate more improvement and more dropouts compared to placebo, but there were no statistically significant differences.

Reviewer's conclusions: Cyclofenil is not effective in the treatment of Raynaud's phenomenon secondary to scleroderma.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1.1
1.1. Analysis
Comparison 1 Cyclofenil vs. Placebo, Outcome 1 % improvement (physician global).
1.2
1.2. Analysis
Comparison 1 Cyclofenil vs. Placebo, Outcome 2 dropouts (because of side effects).
1.3
1.3. Analysis
Comparison 1 Cyclofenil vs. Placebo, Outcome 3 Improvement (ulcers).
See this image and copyright information in PMC

References

References to studies included in this review

Blom‐Bulow 1981 {published data only}
    1. Blom‐Bulow B, Oberg K, Wollheim FA, Persson B, Jonson B, Malmberg P, Bostrom H, Herbai G. Cyclofenil versus placebo in progressive systemic sclerosis. A one‐year double‐blind crossover study of 27 patients. Acta Medica Scandinavica 1981;210(5):419‐428. - PubMed

References to studies excluded from this review

Gibson 1983 {published data only}
    1. Gibson T, Grahame R. Cyclofenil treatment of scleroderma‐‐a controlled study. British Journal of Rheumatology 1983;22(4):218‐223. - PubMed
Kahaleh 1994 {published data only}
    1. Kahaleh MB. Raynaud's phenomenon and vascular disease in scleroderma. Current Opinion in Rheumatology 1994;6:621‐7. - PubMed

Additional references

ACR criteria 1980
    1. Masi AT, Rodnan GP, Medsger TA Jr, et al. ACR Preliminary criteria for the classification of systemic sclerosis (scleroderma): Special article. Arthritis and Rheumatism 1980;23:581‐590. - PubMed
Altman 2001
    1. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbournse D, Gotzsche PC, Lang T. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Annals of Internal Medicine 2001;134:663‐694. - PubMed
Cohen 1988
    1. Cohen J. Statistical Power Analysis for the Behavioural Sciences. Lawrence Erlbaum Associates, Inc., 1988:21‐34.
Dickersin 1994
    1. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286‐91. - PMC - PubMed
Freedman 1984
    1. Freedman RR, Ianni P, Wenig P. Behavioral treatment of Raynaud's phenomenon in scleroderma. Journal of Behavioral Medicine 1984;7(4):343‐53. - PubMed
Jadad 1996
    1. Jadad A, Moore A, Carrol D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1‐12. - PubMed
LeRoy 1992
    1. LeRoy EC, Medsger TA. Raynaud's Phenomenon: A Prosposal for Classification. Clinical and Experimental Rheumatology 1992;10:485‐488. - PubMed
Medsger 1985
    1. Medsger TA Jr. Systemic sclerosis (scleroderma), eosinophilic fasciitis, and calcinosis. In: McCarty DJ editor(s). Arthritis and Allied Conditions. 10th Edition. Philadelphia: Lea and Febiger, 1985:944‐1036.
Petitti 1994
    1. Petitti D. Meta‐analysis, decision analysis, and cost‐effectiveness analysis: methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994:90‐114.

Publication types

MeSH terms